Peri-implant Bone Remodeling after Total Hip Replacement Combined with Systemic Alendronate Treatment: A Finite Element Analysis

Peter, Bastian; Ramaniraka, N. A.; Rakotomanana, L.; Zambelli, Pierre‐Yves; Pioletti, Dominique P.

doi:10.1080/1025584042000205327

Cited by 22 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the success rate in hip replacement is very high, implant failure or implant loosening still happens [12]. Generally, the average life span of an implant is about 15 years; eventually it wears out.…”

Section: C406mentioning

confidence: 99%

Computer simulation of polymethylmethacrylate bone cement flow through femoral canal and cancellous bone

Srimongkol¹,

Wiwatanapataphee²,

Wu³

2006

ANZIAMJ

View full text Add to dashboard Cite

Polymethylmethacrylate bone cements have been widely used in orthopaedic surgery for the fixation of artificial joints such as hip replacement. Understanding the flow of cement is crucial to the success of the process, as the cement flow determines the final shape of the filling and consequently the strength and durability of the structure. A mathematical model based on the finite element method is developed to simulate the flow of cement through femoral canal and cancellous bone. The cement is assumed as a power law non-Newtonian fluid * Dept. and its flow in femoral canal is governed by the non-linear NavierStokes equations. The cancellous bone is modelled as a porous media and the Brinkman equations are used to describe the flow of cement through the bone. Based on the model developed, various numerical experiments were carried out to investigate the influence of cement property and surgical conditions on flow pattern, pressure distribution and shear rate.

show abstract

Section: C406mentioning

confidence: 99%

Computer simulation of polymethylmethacrylate bone cement flow through femoral canal and cancellous bone

Srimongkol¹,

Wiwatanapataphee²,

Wu³

2006

ANZIAMJ

View full text Add to dashboard Cite

show abstract

“…Pemberian secara sistemik klodronat, risedronat dan alendronat pada penelitian eksperimental dengan hewan coba telah terbukti efektif mencegah kehilangan tulang karena peradangan periodontal dengan cara penghambatan aktivitas osteoklas. [11][12][13][14][15][16][17][18][19] Pemberian secara sistemik berefek terhadap seluruh kerangka tubuh, sehingga pemberian secara topikal merupakan pilihan untuk merawat kehilangan tulang periodontal. 20 Pada perawatan ortodontik, kegagalan perawatan dapat disebabkan oleh terjadinya gerakan yang tidak diinginkan dari gigi penjangkar selama perawatan ortodonti (loss of anchorage) dan terjadinya gerakan gigi ke posisi semula seperti sebelum perawatan (relapse).…”

unclassified

Bisphosphonate: Brief Review of Its Development for Usage in Dentistry

Utari

2013

J Dent Indones

View full text Add to dashboard Cite

Bisphosphonate (BP) is a class of drug that prevent the loss of bone mass. It inhibits the resorption of bone by encouraging osteoclast to undergo apoptosis. Considering that oral diseases and dental procedures may lead to teeth instability whereas alveolar bone is the main tooth supporting tissue, forceful indication of this drug is for preventing and minimizing bone resorption following oral surgery and relapse movement in orthodontic treatment. Clinical use of BP in dentistry is limited by risk of osteonecrosis of the jaw (ONJ) and of its systemic effects such as an increase of the bone mineral density in another bone area. Topical application with local effect would seem the choice of administration route for usage in dentistry. Until recently, no clinical usage of topical BP has been studied, however some experimental laboratory studies proved that this drug would be beneficial in a wide scope of dental treatments. ABSTRAKBisfosfonat: tinjauan singkat pengembangan penggunaanya di bidang kedokteran gigi. Obat ini menghambat resorpsi tulang dengan memicu osteoklas mengalami apoptosis. Bisfosfonat (BP) memiliki potensi manfaat besar dalam dunia kedokteran gigi mengingat bahwa baik penyakit maupun prosedur perawatan gigi dapat menyebabkan ketidakstabilan gigi dan diketahui bahwa tulang alveolar merupakan jaringan pendukung utama gigi. Indikasi kuat dari obat ini adalah untuk mencegah dan meminimalkan resorpsi tulang setelah operasi bedah mulut dan gerakan relaps setelah perawatan ortodontik. Penggunaan secara klinis BP dalam kedokteran gigi dibatasi oleh risiko osteonekrosis rahang (ONJ) dan efek sistemik seperti peningkatan kepadatan mineral tulang di daerah lain. Aplikasi topikal dengan efek lokal tampak sebagai pilihan solusi untuk risiko di atas. Penelitian terbaru dari BP topikal belum sampai pada penggunaan klinis, tetapi dari beberapa penelitian pada hewan coba telah memberikan bukti bahwa obat ini akan bermanfaat dalam lingkup yang luas pada perawatan kedokteran gigi.Key words: alveolar bone, bisphosphonate, topical administration PENDAHULUAN Bisfosfonat (BP) adalah kelompok obat yang memiliki kemampuan mencegah hilangnya massa tulang dengan mekanisme penghambatan osteoklas sehingga menekan turnover tulang.1 BP paling sering digunakan untuk pengobatan osteoporosis, penyakit Paget's, metastasis keganasan pada tulang dan kondisi-kondisi lain yang menyebabkan kerapuhan tulang. 2,3Walaupun sudah banyak laporan adanya efek samping penggunaan BP yang terkait dengan bidang kedokteran gigi, namun penggunaan obat ini untuk kepentingan perawatan di dalam rongga mulut juga sedang diteliti. Dalam dunia kedokteran gigi, penggunaan BP kemungkinan dapat memberikan harapan dalam upaya menstabilkan gigi dalam tulang alveolar. Masalah stabilitas gigi selalu menjadi perhatian di semua cabang ilmu kedokteran gigi. Ketidakstabilan gigi dapat terjadi akibat penyakit maupun tindakan yang dilakukan oleh dokter gigi. Salah satu faktor penentu utama stabilitas gigi adalah keutuhan tulang alveolar. BP membuka harapan untu...

show abstract

“…[3,4] Femoral stems have been developed and engineered to reduce bone resorption in the proximal part and enhance the long-term survival of the implant through specific design modifications. [5,6,7] In spite of these changes, osteolysis resulting from byproducts of wear is not a regional or design-specific process and may present a continuing concern. [8,9,10,11,12] In a typical osteoarthritic patient undergoing THA, the greatest bone loss from implants of wear and stress shielding occurs during the first 3-6 months post-surgery.…”

Section: Introductionmentioning

confidence: 99%

Delayed Administration of Risedronate Does Not Restore Bone Loss In Patients Following Total Hip Arthroplasty - A randomized, double blinded clinical study

Lionberger¹,

Liao²,

Eggers³

et al. 2013

Reconstructive Review

View full text Add to dashboard Cite

Background: Periprosthetic bone loss after total hip arthroplasty (THA) increases the risk of serious post-operative complications. Previous studies have reported the beneficial effect of risedronate therapy to improve periprosthetic bone mineral density (BMD) around new implants. The current study is to evaluate the effect of risedronate treatment in enhancing mature well fixed THA implants one year or more after implantation.Methods and Results: A total of 32 osteoarthritic patients received total hip replacement surgeries and were enrolled from the primary investigator's clinical practice between February and September 2007. All eligible patients who met the inclusion criteria underwent total hip arthroplasty for reasons other than low traumatic hip fracture due to osteoporosis with normal or osteopenic lumbar spine BMD scores. Subjects received oral risedronate or a placebo with daily calcium plus Vitamin D. DEXA BMD scanning and bone-specific biomarkers, NTx and ALK phosphatase were collected at 6 and 12 months post-surgery. The result showed that risedronate did not increase BMD values of operative femur nor levels in NTx or ALK phosphatase.Conclusions: This study suggests that risedronate treatment is not effective in preventing periprosthetic bone loss nor enhancing existing density in well fixed osteointegrated following total hip arthroplasty.

show abstract

Peri-implant Bone Remodeling after Total Hip Replacement Combined with Systemic Alendronate Treatment: A Finite Element Analysis

Cited by 22 publications

References 18 publications

Computer simulation of polymethylmethacrylate bone cement flow through femoral canal and cancellous bone

Computer simulation of polymethylmethacrylate bone cement flow through femoral canal and cancellous bone

Bisphosphonate: Brief Review of Its Development for Usage in Dentistry

Delayed Administration of Risedronate Does Not Restore Bone Loss In Patients Following Total Hip Arthroplasty - A randomized, double blinded clinical study

Contact Info

Product

Resources

About